citric acid, anhydrous has been researched along with Syndrome in 6 studies
Citric Acid: A key intermediate in metabolism. It is an acid compound found in citrus fruits. The salts of citric acid (citrates) can be used as anticoagulants due to their calcium chelating ability.
citric acid : A tricarboxylic acid that is propane-1,2,3-tricarboxylic acid bearing a hydroxy substituent at position 2. It is an important metabolite in the pathway of all aerobic organisms.
Syndrome: A characteristic symptom complex.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We randomized 70 acute coronary syndrome patients undergoing percutaneous coronary intervention to receive abciximab, eptifibatide, or tirofiban at doses used in the Evaluation of Platelet IIb/IIIa Inhibitor for STENTing (EPISTENT), Platelet glycoprotein IIb/IIIa in Unstable angina Receptor Suppression Using Integrilin Therapy (PURSUIT), and Platelet Receptor Inhibition in ischemic Syndrome Management in Patients Limited by Unstable Signs and symptoms (PRISM-PLUS)/Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis (RESTORE) trials, respectively." | 9.10 | Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, an ( Batchelor, WB; Califf, RM; Cantor, WJ; Davidian, M; DiBattiste, PM; Dillard, P; Gretler, D; Harrington, RA; Huang, Y; Larsen, RL; Mantell, RM; Ohman, EM; Sketch, MH; Tcheng, JE; Tolleson, TR; Zhang, D; Zidar, JP, 2002) |
| "We randomized 70 acute coronary syndrome patients undergoing percutaneous coronary intervention to receive abciximab, eptifibatide, or tirofiban at doses used in the Evaluation of Platelet IIb/IIIa Inhibitor for STENTing (EPISTENT), Platelet glycoprotein IIb/IIIa in Unstable angina Receptor Suppression Using Integrilin Therapy (PURSUIT), and Platelet Receptor Inhibition in ischemic Syndrome Management in Patients Limited by Unstable Signs and symptoms (PRISM-PLUS)/Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis (RESTORE) trials, respectively." | 5.10 | Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, an ( Batchelor, WB; Califf, RM; Cantor, WJ; Davidian, M; DiBattiste, PM; Dillard, P; Gretler, D; Harrington, RA; Huang, Y; Larsen, RL; Mantell, RM; Ohman, EM; Sketch, MH; Tcheng, JE; Tolleson, TR; Zhang, D; Zidar, JP, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (16.67) | 18.7374 |
| 1990's | 2 (33.33) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abudu, H | 1 |
| Aximujiang, K | 1 |
| Ahemaiti, A | 1 |
| Wu, G | 1 |
| Zhang, J | 1 |
| Yunusi, K | 1 |
| Chung, KF | 1 |
| Batchelor, WB | 1 |
| Tolleson, TR | 1 |
| Huang, Y | 1 |
| Larsen, RL | 1 |
| Mantell, RM | 1 |
| Dillard, P | 1 |
| Davidian, M | 1 |
| Zhang, D | 1 |
| Cantor, WJ | 1 |
| Sketch, MH | 1 |
| Ohman, EM | 1 |
| Zidar, JP | 1 |
| Gretler, D | 1 |
| DiBattiste, PM | 1 |
| Tcheng, JE | 1 |
| Califf, RM | 1 |
| Harrington, RA | 1 |
| NISHI, A | 1 |
| Stoffel, M | 1 |
| Karayiorgou, M | 1 |
| Espinosa, R | 1 |
| Beau, MM | 1 |
| Uren, RF | 1 |
| Howman-Giles, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Chronic Cough and Small Fiber Neuropathy[NCT03787511] | 60 participants (Anticipated) | Interventional | 2019-03-05 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for citric acid, anhydrous and Syndrome
| Article | Year |
|---|---|
Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, an
Topics: Abciximab; Acute Disease; Aged; Amino Acid Chloromethyl Ketones; Angina, Unstable; Angioplasty, Ball | 2002 |
5 other studies available for citric acid, anhydrous and Syndrome
| Article | Year |
|---|---|
[Metabonomic analysis of the urine from rat model with abnormal sapra syndrome].
Topics: Amino Acids; Animals; Citric Acid; Creatine; Disease Models, Animal; Energy Metabolism; Glutamine; G | 2017 |
Chronic 'cough hypersensitivity syndrome': a more precise label for chronic cough.
Topics: Animals; Antitussive Agents; Capsaicin; Chronic Disease; Citric Acid; Cough; Humans; Quality of Life | 2011 |
[THE CLINICAL AND EXPERIMENTAL STUDIES ON THE CITRIC ACID METABOLISM IN EKIRI-LIKE SYNDROME].
Topics: Animals; Blood Chemical Analysis; Child; Citrates; Citric Acid; Diarrhea; Diarrhea, Infantile; Dipht | 1963 |
The human mitochondrial citrate transporter gene (SLC20A3) maps to chromosome band 22q11 within a region implicated in DiGeorge syndrome, velo-cardio-facial syndrome and schizophrenia.
Topics: Abnormalities, Multiple; Animals; Base Sequence; Carrier Proteins; Chromosome Mapping; Chromosomes, | 1996 |
Pott's puffy tumor. Scintigraphic findings.
Topics: Abscess; Adolescent; Child; Citrates; Citric Acid; Edema; Frontal Bone; Gallium; Humans; Male; Osteo | 1992 |